Author: A Perren | MedLuna.com

1.

Retraction Note: Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer

Galvan J, Zlobec I, Wartenberg M, Lugli A, Gloor B, Perren A, et al.

Br J Cancer . 2025 Feb; PMID: 39948240

No abstract available.

2.

NETest in advanced high-grade gastroenteropancreatic neuroendocrine neoplasms

Sorbye H, Hjortland G, Vestermark L, Sundlov A, Assmus J, Couvelard A, et al.

J Neuroendocrinol . 2024 Jun; 36(11):e13428. PMID: 38937137

Molecular blood biomarkers are lacking for high-grade (HG) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN). To histologically distinguish between neuroendocrine carcinoma (NEC), neuroendocrine tumors G3 (NET G3), adenocarcinoma and MINEN is often...

3.

Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence

Merola E, Pascher A, Rinke A, Bartsch D, Zerbi A, Nappo G, et al.

Ann Surg Oncol . 2022 May; 29(9):5568-5577. PMID: 35583694

Background: Surgery with radical intent is the only potentially curative option for entero-pancreatic neuroendocrine tumors (EP-NETs) but many patients develop recurrence even after many years. The subset of patients at...

4.

Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Pavel M, Oberg K, Falconi M, Krenning E, Sundin A, Perren A, et al.

Ann Oncol . 2020 Apr; 31(7):844-860. PMID: 32272208

No abstract available.

5.

Poorly differentiated thyroid carcinoma : An underdiagnosed entity

Dettmer M, Schmitt A, Komminoth P, Perren A

Pathologe . 2019 Jul; 41(Suppl 1):1-8. PMID: 31273418

Poorly differentiated thyroid carcinomas (PDTCs) are a rare subtype of thyroid carcinomas that are biologically situated between well-differentiated papillary/follicular thyroid carcinomas and anaplastic thyroid carcinomas (ATCs).The diagnosis of conventional as...

6.

[Poorly differentiated thyroid carcinoma : An underdiagnosed entity. German version]

Dettmer M, Schmitt A, Komminoth P, Perren A

Pathologe . 2019 May; 40(3):227-234. PMID: 31093689

Poorly differentiated thyroid carcinomas (PDTCs) are a rare subtype of thyroid carcinomas that are biologically situated between well-differentiated papillary/follicular thyroid carcinomas and anaplastic thyroid carcinomas (ATCs).The diagnosis of conventional as...

7.

[Lean management in the pathology laboratory]

Blank A, Dawson H, Hammer C, Perren A, Lugli A

Pathologe . 2017 Oct; 38(6):540-544. PMID: 29043447

No abstract available.

8.

Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas

Galleberg R, Knigge U, Tiensuu Janson E, Vestermark L, Haugvik S, Ladekarl M, et al.

Eur J Surg Oncol . 2017 May; 43(9):1682-1689. PMID: 28522174

Background: Gastroenteropancreatic neuroendocrine carcinomas (GEP-NEC) are generally characterized by synchronous metastases, high aggressiveness and a dismal prognosis. Current international guidelines do not recommend surgical treatment of liver metastases, however the...

9.

Hypo-methylation mediates chromosomal instability in pancreatic NET

Marinoni I, Wiederkeher A, Wiedmer T, Pantasis S, Di Domenico A, Frank R, et al.

Endocr Relat Cancer . 2017 Jan; 24(3):137-146. PMID: 28115389

DAXX and or ATRX loss occur in 40% of pancreatic neuroendocrine tumors (PanNETs). PanNETs negative for DAXX or ATRX show an increased risk of relapse. The tumor-associated pathways activated upon...

10.

ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum

Niederle B, Pape U, Costa F, Gross D, Kelestimur F, Knigge U, et al.

Neuroendocrinology . 2016 Jan; 103(2):125-38. PMID: 26758972

No abstract available.